Childhood diabetes crisis stalks Europe, more screening urged euractiv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from euractiv.com Daily Mail and Mail on Sunday newspapers.
For children and adolescents with newly diagnosed type 1 diabetes, two 12-day courses of teplizumab show benefit for preservation of beta (β)-cell function.
Furthermore, 94.9 and 79.2% of patients treated with teplizumab and placebo, respectively, maintained a clinically meaningful peak C-peptide level of 0.2 pmol/mL or greater.